What is a common FDA label indication for the combination of Hydrochlorothiazide and Lisinopril?

The combination of Hydrochlorothiazide and Lisinopril is commonly indicated for the management of hypertension. While the specific mention of "ST-segment elevation MI" relates to myocardial infarction, which pertains to emergency intervention rather than long-term control of blood pressure, it is important to clarify the appropriate context.

Lisinopril is an ACE inhibitor that helps to manage high blood pressure and also provides renal protection in patients with diabetic nephropathy. Hydrochlorothiazide is a thiazide diuretic that reduces blood pressure by encouraging the excretion of sodium and water, leading to decreased blood volume.

In the context of the options provided, mentioning a myocardial infarction is relevant since managing hypertension is crucial in secondary prevention of cardiovascular events, including myocardial infarctions. However, Hydrochlorothiazide and Lisinopril are not specifically indicated for acute management of ST-segment elevation myocardial infarction; they play a role in the long-term management of blood pressure after such events.

The key takeaway is that combining these medications effectively addresses hypertension, which is a risk factor for cardiovascular disease, including myocardial infarction, making the point about their relevance in that context valid.